Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a chronic progressive disease which is associated with significant premature mortality and morbidity. Diabetes patient care is a complex process, mainly aiming to attain euglycemia with glycated hemoglobin (HbA1c) levels at 7% \[[@CR1], [@CR2]\]. Current treatment guidelines encourage healthcare providers and patients to co-develop a "patient-centered" diabetes care plan \[[@CR2]\], with the responsibility for the daily self-management activities transferred from the healthcare provider to the patient \[[@CR3], [@CR4]\].

National and international diabetes associations recognize patient education delivered in the context of standard care, or in a structured way, as a key component of diabetes care and recommend that it should be provided to all patients \[[@CR2], [@CR5], [@CR6]\]. In standard-of-care, patient education comprises basic information on lifestyle modification and disease management. In contrast, structured patient education addresses a multitude of patient characteristics and other factors that influence each person's ability to perform the required self-management activities \[[@CR6]\]. Structured patient education can be provided to groups of patients or individually, with each mode having advantages and disadvantages \[[@CR7]--[@CR9]\].

Adherence to the complex T2DM treatment regimen may be overwhelming for patients. In fact, adherence rates have been reported to range from 36% to 93% in patients that remained on treatment with oral glucose-lowering agents for 6--24 months \[[@CR10]\]. Adherence to treatment is influenced by a variety of factors, including patient characteristics, characteristics of the treatment regimen, features of the disease, prescriber-level factors (including patient--physician relationship), and the clinical setting \[[@CR11]\]. Rubin \[[@CR12]\] proposed that "education is a useful resource for addressing all barriers to treatment adherence." Furthermore, the author concluded that self-management education can ultimately lead to improved self-care behavior, glycemic control, and positive patient outcomes.

In Greece, the prevalence of T2DM is estimated at approximately 7.0% \[[@CR13]\], and the prevalence of undiagnosed cases is possibly even higher \[[@CR14]\]. The level of diabetes education appears to be poor among patients who are treated with oral glucose-lowering agents \[[@CR15]\]. However, Greek patients have been shown to benefit from diabetes education; a relatively recent study reported that a structured 6-h education program delivered in small groups of patients was more effective than standard-of-care in improving glycemic control \[[@CR16]\]. Furthermore, a non-experimental study reported that patients adhered to certain aspects of self-management (e.g., diet, blood test exams, regarding self-care etc.) while adherence to exercise and foot management were low \[[@CR17]\]. Currently, no studies could be identified assessing the effect of patient education on adherence in Greek patients with T2DM.

This study aimed at evaluating the results of a systematic education program and telephone support on self-reported adherence to treatment with oral glucose-lowering agents in patients with T2DM. In addition, the study sought to investigate the impact of education on other biomedical variables, health-related quality of life, and diabetes treatment satisfaction patient-reported outcomes.

Methods {#Sec2}
=======

Study Design and Participants {#Sec3}
-----------------------------

ADVICE was a non-interventional, cluster randomized, parallel-group study conducted in 45 primary and secondary outpatient diabetes care centers throughout Greece. Eligible patients were 18 years of age or older, with uncontrolled T2DM (HbA1c \> 7%), treated with oral glucose-lowering medications for at least 1 year prior to enrollment. Key exclusion criteria were type 1 diabetes mellitus (T1DM), gestational diabetes, hospitalized patients, and history of alcohol or drug abuse within the year preceding enrolment; pregnant, breastfeeding, or female patients with childbearing potential were also excluded.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013, and with the standards of Good Pharmacoepidemiology Practice; all applicable local laws, rules, and regulations relating to the conduct of the clinical study. Informed consent was obtained from all patients for being included in the study and ethical approval was obtained from all participating centers. Further details regarding the ethics committees from all the participating centers who approved this study can be found in the Supplementary Materials.

Randomization {#Sec4}
-------------

Randomization took place at center level; centers were randomly assigned (with the use of an electronic algorithm) in a ratio of 1:1 to provide either standard-of-care treatment (control group) or standard-of-care along with a systematic patient education program (empowerment group) to patients with T2DM. Investigators decided independently on the patients' treatment regimen and goals.

In the empowerment group, investigators utilized a sponsor-approved educational material on diabetes which was based on the national and international recommendations. The material included information on disease knowledge, diet and exercise, use of medications and adherence to treatment, adverse events related to treatment, and coping with disease- or treatment-related stress. Investigators were trained on its use for education of their patients during study visits. This material was also provided to patients for further reading following enrollment.

In addition, physicians in the empowerment group were communicating via telephone (approximately bi-weekly) with the patients to support them on the attainment of the treatment goals; predetermined discussion topics included diet, physical activity, adherence to prescribed medication etc. A telephone contact log was used for this purpose.

Procedures {#Sec5}
----------

The study follow-up period lasted 8 months. Demographic and biomedical data and patient-reported outcome questionnaires were collected by the investigators at study entry (baseline visit) and at 4- and at 8-month (± 1 week) visits; the two aforementioned visits were held in the context of standard-of-care. Demographic data included age, gender, age at time of T2DM diagnosis, disease duration (recorded only at baseline), body mass index, waist and hip size, smoking habits, alcohol consumption, and physical activity. Biomedical data included measurements of HbA1c, fasting plasma glucose (FPG), postprandial glucose (PPG), blood lipids (total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides), microalbuminuria, blood pressure, heart rate, comorbidities, and preventative screening (lower extremity and eye examinations, and assessment for atherosclerotic cardiovascular disease).

The patient-reported outcomes included in the analysis were adherence to treatment, health-related status, and treatment satisfaction. Adherence to treatment was assessed with the four-item Morisky Medication Adherence Scale (MMAS-4; score range 0--4; higher scores indicate higher adherence) \[[@CR18]\]; on the basis of their MMAS-4 score, patients were classified into high, medium, or low adherence (MMAS-4 scores 4, 2--3, and 0--1, respectively). Health-related quality of life was assessed with the five-level EQ-5D (EQ-5D-5L) questionnaire and the visual analogue scale (EQ-VAS) \[[@CR19]\]. Finally, treatment satisfaction was assessed with the Diabetes Treatment Satisfaction Questionnaire status (DTSQs; score range 0--36; higher scores indicate higher satisfaction) and change (DTSQc) versions \[[@CR20], [@CR21]\].

Objectives {#Sec6}
----------

The primary objective was to compare the self-reported adherence to the treatment between the empowerment and control groups, on the basis of the proportions of patients with high versus medium/low self-reported adherence to the treatment at 4 months.

The key secondary objectives included (1) the comparison of the proportion of patients with high versus medium/low adherence to treatment at 8 months between the empowerment control groups and (2) the within-group change in the proportion of patients with high versus medium/low adherence from baseline to 4 and 8 months. Other secondary objectives were the comparison of treatment satisfaction and health-related quality of life status between the empowerment and control groups, at 4 and 8 months; the within-group change of treatment satisfaction and health-related quality of life status from baseline to 4 and 8 months; the comparison of the proportion of patients achieving predefined targets for diabetes, lipid, and blood pressure variables between the empowerment and control groups, at 4 and 8 months. These targets were HbA1c \< 7.0%; blood glucose \< 110 mg/dl; LDL-C \< 100 mg/dl (\< 70 mg/dl for patients with diabetes and cardiovascular disease); and systolic blood pressure (SBP) \< 130 mmHg (default target for blood pressure, systolic/diastolic blood pressure \< 125/75 mmHg in case of renal dysfunction, proteinuria \> 1 g/24 h).

Statistical Analysis {#Sec7}
--------------------

The sample size was estimated on the assumptions that among patients with poorly controlled diabetes the proportion of patients with high/medium adherence (defined with MMAS-4) is approximately 60%, the difference in the between-group ratio of patients with high/medium adherence would be at least 15%, and the rate of data loss would be at maximum approximately 10% of the required sample. When a two-sided chi-square test was used with type I error 0.05 and power 0.8, the sample size needed to identify the specified difference between the two proportions was 152 for each group. To account for clustering effects from the randomization scheme, an intraclass correlation coefficient of 0.04 was applied; this increased the sample size to 207 patients. Therefore, the required sample size per arm was 230 patients and the total for both groups was 460 patients with 46 research sites recruiting 10 patients each. This assumption was based on available bibliography data suggesting that the prevalence of self-reported medication nonadherence with the use of MMAS-4 in older adults ranges from 33% to 57% \[[@CR22]--[@CR24]\].

Descriptive analysis was performed to summarize demographic, clinical variables and patient-reported outcomes of study patients. Continuous variables are presented as mean with standard deviation (SD) and categorical variables as counts and proportions.

The association between categorical variables was assessed using the chi-square (*χ*^2^) test. The McNemar test was used for the association of a categorical variable between two time points. Differences of continuous variables at different time points were evaluated with Wilcoxon signed rank test for related samples, while the differences of continuous variables between two groups were evaluated with the *U* Mann--Whitney test for independent samples. The Breslow-Day test for homogeneity of odds ratios was used to compare the change in the rates of high adherence or intense physical activity from baseline to 4 or 8 months.

As a result of the study design, a hierarchical, multilevel, mixed effects model was fitted to further investigate the efficacy of the educational intervention after controlling for baseline differences between the experimental and the control group and for variability in clinical practice among centers. Factors that were associated with a high adherence rate at 4 months (*p* \< 0.1) were included in the multivariate model, with random effects fitted for the study centers (further details are included as Supplementary Material).

All statistical tests were two-sided and were performed at a 0.05 significance level. The *p* values were reported, even for non-significant results, rounded to three decimals unless the *p* value was less than 0.001 (in such case *p* \< 0.001 was reported). No adjustment for multiple testing was performed. Analysis was performed with SAS^®^ version 9.4.

Results {#Sec8}
=======

Patient Demographic and Biomedical Characteristics at Baseline {#Sec9}
--------------------------------------------------------------

Forty-five centers were recruited in the study and a total of 457 patients with T2DM were enrolled (Table [1](#Tab1){ref-type="table"}). Female patients accounted for 43.5% of the entire study population. Mean (SD) baseline characteristics were age, 62.7 (11.4) years; duration of diabetes, 8.5 (6.5) years; and HbA1c, 7.8 (0.9) %. Comorbidities and diabetes complications occurred in 75.7% and 7.7% of patients, respectively. The most common comorbidities were arterial hypertension (44.8%), dyslipidemia (39.0%), ischemic heart disease (4.6%), and myocardial infarction (1.7%), while the most common diabetes-related complications were nephropathy (31.4%), retinopathy (25.7%), and neuropathy (17.1%).Table 1Patient characteristics at baseline, overall and per groupAll patients\
(*N* = 457)Control group\
(*n* = 227)Empowerment group\
(*n* = 230)*p* valueDemographic data Age (SD)62.7 (11.4)63.8 (10.1)61.5 (6.7)0.047 Female (%)43.542.344.80.591 BMI (kg/m^2^)30.6 (5.3)30.3 (5.0)30.8 (5.6)0.203 Diabetes duration (SD)8.5 (6.5)8.8 (6.3)8.3 (6.7)0.152 Diabetes history in 1st degree relatives (%)53.854.253.50.952Biomedical characteristics Comorbidities, all (%)75.778.972.60.120 Diabetes complications, all (%)7.78.47.00.570 Physical training  Intense activity for ≥ 20 min, once or more times per week109 (24.0)52 (23.0)57 (24.9)0.638  No or limited weekly activity346 (76.0)174 (77.0)172 (75.1) Patients on specific diabetes diet (%)47.553.741.30.028 Smoking0.340  Current14.411.917.0  Former21.022.519.6  Never61.763.460.0 Alcohol consumption0.004  Daily4.24.04.3  Never56.965.248.7  Occasionally36.829.144.3 Diabetes treatments (%)  Biguanides65.964.867.0  DPP-446.043.248.7  SGLT-222.823.821.7  Insulin (all types)1.80.92.6 HbA1c7.8 (0.9)7.7 (0.8)8.0 (1.0)0.001 FPG (mg/dl)149.1 (40.5)140.9 (31.0)157.0 (46.6)0.001 PPG (mg/dl)175.1 (50.6)162.1 (30.9)188.3 (62.2)0.001 Triglycerides (mg/dl)162.9 (81.3)156 (68.3)169.8 (92.2)0.446 HDL-C (mg/dl)45.7 (11.3)46.4 (10.9)45.0 (11.7)0.261 LDL-C (mg/dl)103.6 (31.6)100.5 (29.7)106.6 (33.1)0.108 TC (mg/dl)183.3 (36.2)180.8 (33.6)185.8 (38.6)0.159 DBP (mmHg)79.1 (8.2)79.5 (8.4)78.8 (8.0)0.766 SBP (mmHg)131.4 (12.9)132.0 (13.3)130.9 (12.5)0.521Patient-reported outcomes  MMAS-4 score3.2 (1.1)3.2 (1.1)3.2 (1.0)0.849  EQ-5D-5L score0.81 (0.19)0.82 (0.18)0.80 (0.20)0.376  EQ-VAS score75.8 (16.7)78.8 (16.1)72.9 (16.8)0.000  DTSQs score27.1 (6.4)29.1 (6.7)25.0 (6.7)0.000All data are mean (SD) unless otherwise shown. *p* values are for control versus empowerment group comparison*DBP* diastolic blood pressure, *DTSQs* Diabetes Treatment Satisfaction Questionnaire status version, *EQ-5D-5L* EuroQol 5-dimension, 5-level scale, *EQ-VAS* EuroQol visual analogue scale, *FPG* fasting plasma glucose, *HbA1c* glycated hemoglobin, *HDL* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *MMAS-4* 4-item Morisky Medication Adherence Scale, *N* total number of patients, *n* number of patients in specified group, *PPG* postprandial glucose, *TC* total cholesterol, *TG* triglycerides, *SD* standard deviation, *SBP* systolic blood pressure

Per study design, 23 and 22 centers were randomly assigned to the control and empowerment groups, respectively; as a result of this randomization, 227 and 230 patients were allocated in the control and empowerment patient groups, respectively.

At baseline, certain patient characteristics differed between groups (Table [1](#Tab1){ref-type="table"}). Age and occasional alcohol consumption were significantly (*p* = 0.047 and *p* = 0.004, respectively) higher in the empowerment group, while the use of specific diabetes diet was more common in the control group (*p* = 0.028). Regarding other biomedical characteristics, HbA1c, FPG, and PPG levels were significantly higher in the empowerment versus the control group (*p* = 0.001 for all comparisons; Table [1](#Tab1){ref-type="table"}).

With respect to the patient-reported outcomes at baseline, the MMAS-4 and EQ-5D-5L scores were not statistically different between groups (*p* = 0.849 and *p* = 0.376, respectively; Table [1](#Tab1){ref-type="table"}). In contrast, the EQ-VAS and DTSQs scores were significantly higher for the control versus the empowerment group at baseline (*p* \< 0.001 for both comparisons).

Patient Support During Follow-Up Period {#Sec10}
---------------------------------------

Investigators in the empowerment group performed regular (approximately bi-weekly) telephone support sessions with their patients during follow-up. On average, 15.3 (2.8) telephone sessions were performed per patient in this group. The overall frequency of topics discussed during these sessions were diet, 93.0%; physical activity, 88.9%; adherence to prescribed medication, 81.3%; smoking habits were not a frequent subject of discussion (28.8%).

Improvement in Self-Reported Adherence Rates During Follow-Up {#Sec11}
-------------------------------------------------------------

Although the mean baseline MMAS-4 scores were similar between groups, the mean score for the empowerment group was significantly higher compared to control group at 4 months (*p* = 0.023) and 8 months (*p* = 0.043) (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Per group improvements in self-reported adherence from baseline to 4 or 8 months. **a** Per group improvements in mean MMAS-4 scores from baseline to 4 and 8 months. **b** Per group change in proportion of patients with high adherence from baseline to 4 or 8 months. High adherence was defined as MMAS-4 score of 4. *p* values in **a** are for empowerment versus control group. *p* values in **b** are based on Breslow-Day *t* test for group comparison. *p* values in bold indicate statistical significance. T bars denote the standard deviation

After controlling for the effect of differences in the clinical practice and baseline covariates, it was observed that the empowerment group was not statistically significantly associated with higher odds of achieving high adherence at 4 months, compared to the control group (OR = 2.1, 95% CI 0.575--7.670; further details are included as Supplementary Material).

For the assessment of the self-reported adherence levels, patients were classified into high (MMAS-4 score 4) or medium/low (MMAS-4 score 0--3) adherence subgroups (Table [2](#Tab2){ref-type="table"}). At baseline, the proportions of patients with high adherence were similar between the control and empowerment groups (57.3% and 53.9%, respectively; *p* = 0.470). At 4 months (primary objective), the proportion of patients with high adherence was significantly greater in the empowerment than the control group (70.7% versus 61.1%, respectively; *p* = 0.032; Table [2](#Tab2){ref-type="table"}); compared to baseline, the increase in the proportion of patients with high adherence was significantly greater for the empowerment than the control group (16.8% and 3.8%, respectively; Breslow-Day test *p* = 0.04; Fig. [1](#Fig1){ref-type="fig"}b).Table 2Classification of patients into high or medium/low adherence per group, at baseline, 4 and 8 monthsControl group\
(*n* = 227)Empowerment group\
(*n* = 230)*p* valueBaseline High adherence130 (57.3)124 (53.9)0.470 Medium/low adherence97 (42.7)106 (46.1)4 months High adherence135 (61.1)157 (70.7)0.032 Medium/low adherence86 (38.9)65 (29.3)8 months High adherence144 (65.8)157 (72.7)0.117 Medium/low adherence75 (34.2)59 (27.3)All data are *n* (%). Patients were classified into high or medium/low adherence subgroups by means of their baseline MMAS-4 score (high adherence, MMAS-4 score 4; medium/low adherence, MMAS-4 score 0 to \< 3). *p* values are for control versus empowerment group comparison*MMAS-4* four-item Morisky Medication Adherence Scale, *n* number of patients in specified group

At 8 months, the proportions of patients with high adherence were not significantly different between groups (*p* = 0.117; Table [2](#Tab2){ref-type="table"}); similarly, the increases in the proportions of patients with high adherence from baseline were non-significant between the empowerment and control groups (18.8% versus 8.5%, respectively; Breslow-Day test *p* = 0.09; Fig. [1](#Fig1){ref-type="fig"}b).

Improvement in Biomedical Characteristics During Follow-Up {#Sec12}
----------------------------------------------------------

Assessment of other biomedical variables is shown in Table [3](#Tab3){ref-type="table"}. Although the mean HbA1c levels were significantly higher for the empowerment versus the control group at baseline, the between-group differences at 4 and 8 months were non-significant (*p* = 0.724 and *p* = 0.114, respectively). For the empowerment group, the mean HbA1c was reduced to 7.1% at 4 months (− 0.9% from baseline) and to 7.0% at 8 months (− 1.0% from baseline); for the control group, the respective mean HbA1c levels and reductions from baseline were 7.0% (− 0.7%) and 6.9 (− 0.8%). Similarly, the between-group differences in the levels of PPG and FPG at 4 and 8 months were non-significant, albeit that the respective baseline levels were significantly higher for the empowerment versus the control group. No significant between-group differences were observed in other clinical characteristics such as blood pressure, heart rate, and lipidemic profile at 4 and 8 months.Table 3Development of key biomedical characteristics from baseline through to 4 and 8 months per groupPatient group*p* valueControl group\
(*n* = 227)Empowerment group\
(*n* = 230)HbA1c (%) Baseline7.7 (0.8)8.0 (1.0)0.001 4 months7.0 (0.6)7.1 (0.6)0.724 8 months6.9 (0.6)7.0 (0.6)0.114FPG (mg/dl) Baseline140.9 (31.0)157.0 (46.6)0.001 4 months125.7 (21.6)128.1 (23.5)0.318 8 months120.6 (21.6)123.1 (21.9)0.294PPG (mg/dl) Baseline162.1 (30.9)188.3 (62.2)0.001 4 months141.1 (20.4)154.8 (28.8)0.001 8 months141.4 (24.5)149.2 (24.5)0.016TC (mg/dl) Baseline180.8 (33.6)185.8 (38.6)0.159 4 months177.3 (26.3)178.3 (32.7)0.769 8 months172.8 (25.7)179.7 (32.1)0.088TG (mg/dl) Baseline156.0 (68.3)169.8 (92.2)0.446 4 months140.2 (45.8)148.4 (61.4)0.362 8 months137.1 (47.6)144.4 (60.6)0.271HDL-C (mg/dl) Baseline46.4 (10.9)45.0 (11.7)0.261 4 months47.7 (10.2)47.2 (11.7)0.643 8 months47.6 (9.8)47.2 (10.8)0.726LDL-C (mg/dl) Baseline100.5 (29.7)106.6 (33.1)0.108 4 months100.0 (25.1)97.9 (28.5)0.365 8 months94.8 (26.3)101.1 (30.1)0.183DBP (mmHg) Baseline79.5 (8.4)78.8 (8.0)0.766 4 months78.9 (7.7)78.2 (7.2)0.301 8 months78.3 (7.2)78.5 (7.9)0.740SBP (mmHg) Baseline132.0 (13.3)130.9 (12.5)0.521 4 months129.6 (12.1)128.3 (10.7)0.708 8 months129.7 (12.4)129.0 (10.7)0.778Intense physical activity, *n* (%) Baseline52 (23.0)57 (24.9)0.638 4 months56 (25.2)86 (38.7)0.002 8 months59 (26.9)103 (47.2)\< 0.001All data are mean (SD) unless otherwise shown. *p* values are for the control versus the empowerment group comparison*DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *HbA1c* glycated hemoglobin, *HDL* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *n* number of patients in specified group, *PPG* postprandial glucose, *TC* total cholesterol, *TG* triglycerides, *SD* standard deviation, *SBP* systolic blood pressure

The rates of intense physical activity (≥ 20 min once or more times per week) were significantly higher in the empowerment group versus the control group at both 4 months (*p* = 0.002) and 8 (*p* \< 0.001) months (Table [3](#Tab3){ref-type="table"}); compared to baseline, the increases in the proportions of patients with intense physical activity were significantly higher for the empowerment group compared with the control group at 4 months (13.9% and 2.3%, respectively; Breslow-Day test *p* = 0.082) and 8 months (22.5% and 4%, respectively; Breslow-Day test *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Per group change in the proportion of patients with intense physical activity (defined as ≥ 20 min once or more times per week) from baseline to 4 or 8 months. *p* values are based on Breslow-Day *t* test for group comparison

Improvements in Treatment Satisfaction and Other Patient-Reported Outcomes During Follow-Up {#Sec13}
-------------------------------------------------------------------------------------------

The significantly higher treatment satisfaction levels observed at baseline for the control versus the empowerment group were maintained at 4 months (*p* = 0.001) and 8 months (*p* = 0.011). The mean (SD) change from baseline to 4 and 8 months assessed with the DTSQs questionnaire was significantly (*p* \< 0.001) higher for the empowerment versus the control group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Per group change in treatment satisfaction from baseline to 4 or 8 months. DTSQs Diabetes Treatment Satisfaction Questionnaire status. *p* values are for empowerment versus control group

Compared to baseline, the EQ-5D-5L mean score remained stable for both groups, with no significant between-group differences at 4 months (*p* = 0.38) or 8 months (*p* = 0.66). The significantly lower EQ-VAS mean score for the empowerment versus the control group, observed at baseline, was maintained at 4 months (*p* \< 0.001) and 8 months (*p* = 0.001).

Discussion {#Sec14}
==========

The ADVICE study assessed the impact of a structured educational program and telephone support on the self-reported adherence to oral glucose-lowering treatment in patients with T2DM. The main finding was that the increase in the proportion of patients with high adherence from baseline to 4 months was significantly (*p* = 0.04) greater for patients who participated in the education program compared with patients who received only standard-of-care. This between-group difference was maintained at 8 months, albeit at not statistically significant levels.

To our knowledge, only a small number of randomized clinical studies have addressed the impact of structured patient education on adherence to treatment. Tan et al. \[[@CR25]\] assessed the impact of an education program on adherence to treatment in a population of patients with T1DM and T2DM over 3 months versus standard care. Patients in the intervention group received two individual education sessions followed by a telephone follow-up. The educational intervention focused on self-care practices (including medication adherence) and problem-solving skills. Consistent with the main findings of this study, it was reported that patients in the intervention group presented significantly higher adherence rates than patients in the control group, with a greater improvement in adherence rates from baseline. Other randomized clinical studies have also reported that diabetes education improves adherence to treatment in the short term (≤ 6 months) in patients with T2DM \[[@CR26]--[@CR29]\]. It is unclear whether this favorable impact of education on adherence to treatment is sustained in the long term.

With respect to glycemic control, the present study shows that both groups attained similar mean HbA1c levels at 4 and 8 months. As already stated, the HbA1c levels at baseline, along with other variables such as age and alcohol consumption, were significantly lower versus the empowerment group; this difference may have masked any comparative effectiveness of the educational program on glycemic control. Previous studies have shown that face-to-face education (the delivery mode used in the present study) was significantly more effective in the reduction of HbA1c levels and other diabetes-related biomedical characteristics compared with standard-of-care \[[@CR30]--[@CR32]\]. On the contrary, telephone contacts as a means of reinforcement of a previous educational program do not appear to have an additional effect on the HbA1c levels \[[@CR33]\]. With respect to the long-term maintenance of glycemic control, Khunti et al. \[[@CR34]\] reported that most of the improvements seen at 12 months in HbA1c levels were not sustained after 3 years. Clearly, the evaluation of the long-term effect of education on adherence to treatment would be an interesting research topic for future trials.

Another finding of the present study was the significant increase in the proportion of patients in the empowerment group performing intense physical activity at 8 months versus those in the control group. Physical activity is a key constituent of diabetes management as it contributes to improved glycemic control \[[@CR35]\]. A recent study assessing the impact of education on perceived benefits, barriers, and self-efficacy reported significant improvements in the mean metabolic equivalent of task in the intervention versus the control group \[[@CR36]\]. In the present study, this increase in physical activity did not appear to translate into biochemical improvements; however, it is considered that there may be a lag effect and therefore potential improvements would have been apparent beyond 8 months.

Finally, regarding treatment satisfaction, patients in the empowerment group had a significantly lower DTSQs score at baseline versus patients in the control group. As treatment satisfaction is inversely related to HbA1c levels \[[@CR37]\], it is possible that the observed difference in satisfaction levels at baseline may be related to the significantly higher HbA1c levels of the empowerment group. As already stated, the significant difference of the control versus the empowerment group persisted throughout the observation period. Despite this, the change from baseline to 4 or 8 months in terms of treatment satisfaction was significantly higher for the empowerment versus the control group. This finding concurs with the findings of the BENCH-D study \[[@CR38]\], which showed that higher empowerment levels in patients with T2DM were associated with improved treatment satisfaction. The results regarding the quality of life are presented with caution, since the statistically significant difference of EQ-5D VAS might depict the baseline differences between the two groups.

The present study has several limitations. Physicians in the control group may have inadvertently treated their patients in a more than standard-of-care manner with regards to providing relevant information. Despite study protocol clarity, variability in participating physicians' practices, measurements, and delivery of education cannot be ruled out. Selection bias cannot be ruled out with respect to participating centers.

It is possible that the differences in key diabetes variables (HbA1c, FPG, and PPG) at baseline between patients allocated in the empowerment and control groups may have masked the impact of education on these variables. However this study design implies that the empowerment and the control groups may differ in terms of baseline characteristics, and thus this was an expected study feature that was further evaluated using a multilevel mixed model analytical approach. After taking into consideration the variation of clinical practices between the participating sites and baseline covariates, the multivariate analysis showed that the empowerment group was not statistically significantly associated with higher odds of achieving high adherence at 4 months, compared to the control group, even though the estimate of the OR remained favorable for the empowerment group (OR 2.1, 95% CI 0.575--7.670).

Conclusions {#Sec15}
===========

This cluster randomized real-world study provides evidence that a structured educational program may lead to improved short-term adherence to treatment in patients with T2DM. Patients who participated in the educational program experienced greater treatment satisfaction and increased their physical activity levels compared with patients receiving standard care.
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